Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
Baxter
AstraZeneca
Colorcon

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lumicitabine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Lumicitabine?

Lumicitabine is an investigational drug.

There have been 6 clinical trials for Lumicitabine. The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2017.

The most common disease conditions in clinical trials are Respiratory Sounds, Infection, and Communicable Diseases. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].

There are five US patents protecting this investigational drug and ninety-eight international patents.

Recent Clinical Trials for Lumicitabine
TitleSponsorPhase
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human MetapneumovirusJanssen Research & Development, LLCPhase 2
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsJanssen Research & Development, LLCPhase 1

See all Lumicitabine clinical trials

Clinical Trial Summary for Lumicitabine

Top disease conditions for Lumicitabine
Top clinical trial sponsors for Lumicitabine

See all Lumicitabine clinical trials

US Patents for Lumicitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Lumicitabine   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lumicitabine

Drugname Country Document Number Estimated Expiration Related US Patent
Lumicitabine Argentina 089408 2031-12-22   Start Trial
Lumicitabine Australia 2012358803 2031-12-22   Start Trial
Lumicitabine Australia 2013235220 2031-12-22   Start Trial
Lumicitabine Australia 2018203423 2031-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Boehringer Ingelheim
Express Scripts
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.